User login
CHICAGO – An experimental triple-drug regimen with or without ribavirin cured more than 90% of 724 previously untreated patients with hepatitis C genotype 1 who did not have cirrhosis.
And it was done without interferon.
Dr. Bruce R. Bacon called this oral regimen "revolutionary" in an interview during the annual Digestive Disease Week. Dr. Bacon is the James F. King Endowed Chair in Gastroenterology and a professor of medicine at St. Louis University. He was not involved in the study.
Hear his thoughts on treatment with ABT-450 with ritonavir, ombitasvir, and dasabuvir (known as the "three D" regimen) with or without ribavirin.
Dr. Bacon reported financial associations with AbbVie, which is developing the new drugs; Gilead Sciences; and Janssen Pharmaceuticals.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @sherryboschert
CHICAGO – An experimental triple-drug regimen with or without ribavirin cured more than 90% of 724 previously untreated patients with hepatitis C genotype 1 who did not have cirrhosis.
And it was done without interferon.
Dr. Bruce R. Bacon called this oral regimen "revolutionary" in an interview during the annual Digestive Disease Week. Dr. Bacon is the James F. King Endowed Chair in Gastroenterology and a professor of medicine at St. Louis University. He was not involved in the study.
Hear his thoughts on treatment with ABT-450 with ritonavir, ombitasvir, and dasabuvir (known as the "three D" regimen) with or without ribavirin.
Dr. Bacon reported financial associations with AbbVie, which is developing the new drugs; Gilead Sciences; and Janssen Pharmaceuticals.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @sherryboschert
CHICAGO – An experimental triple-drug regimen with or without ribavirin cured more than 90% of 724 previously untreated patients with hepatitis C genotype 1 who did not have cirrhosis.
And it was done without interferon.
Dr. Bruce R. Bacon called this oral regimen "revolutionary" in an interview during the annual Digestive Disease Week. Dr. Bacon is the James F. King Endowed Chair in Gastroenterology and a professor of medicine at St. Louis University. He was not involved in the study.
Hear his thoughts on treatment with ABT-450 with ritonavir, ombitasvir, and dasabuvir (known as the "three D" regimen) with or without ribavirin.
Dr. Bacon reported financial associations with AbbVie, which is developing the new drugs; Gilead Sciences; and Janssen Pharmaceuticals.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @sherryboschert
AT DDW 2014
